David Gobel
Director/Board Member at ORGANOVO HOLDINGS, INC.
Net worth: 20 195 $ as of 2024-03-30
Profile
Founder of Methuselah Capital Management LLC, David Gobel presently is Chairman for Turn Biotechnologies, Inc. Mr. Gobel is also on the board of Organovo Holdings, Inc., Oisin Biotechnologies, Inc. and Leucadia Therapeutics, Inc. and Chief Executive Officer at Methuselah Foundation.
In the past Mr. Gobel held the position of Chief Venture Strategist at Transportation Security Administration.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ORGANOVO HOLDINGS, INC.
0.20% | 2023-11-16 | 19,607 ( 0.20% ) | 20 195 $ | 2024-03-30 |
David Gobel active positions
| Companies | Position | Start |
|---|---|---|
| ORGANOVO HOLDINGS, INC. | Director/Board Member | 2020-09-14 |
Oisin Biotechnologies, Inc.
 Oisin Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Oisin Biotechnologies, Inc. operates as a drug development company. It engages in the provision of biological solutions to degenerative aging conditions. The company was founded by Gary Hudson, Kevin Perrott, Matthew Scholz and John Lewis in 2014 and is headquartered in Seattle, WA. | Director/Board Member | 2014-11-30 |
Methuselah Capital Management LLC
 Methuselah Capital Management LLC Investment ManagersFinance Methuselah Capital Management LLC (Methuselah Fund) is a venture capital firm, a subsidiary of Methuselah Foundation founded in 2016 by Sergio Ruiz and David Gobel. The firm is headquartered in Springfield, Virginia. | Chief Executive Officer | 2016-12-31 |
Leucadia Therapeutics, Inc.
 Leucadia Therapeutics, Inc. Medical SpecialtiesHealth Technology Leucadia Therapeutics, Inc. develops diagnostic algorithm for Alzheimer disease prevention and treatment. The firm?s therapeutic device is under pre-clinical testing to delay or prevent patients with mild cognitive impairment (MCI) from progressing to Alzheimer's disease. The company was founded by Doug Ethell and is headquartered in Delaware. | Director/Board Member | 2015-09-30 |
| Methuselah Foundation | Chief Executive Officer | 2001-08-31 |
Turn Biotechnologies, Inc.
 Turn Biotechnologies, Inc. BiotechnologyHealth Technology Turn Biotechnologies, Inc. engages in the development of solutions for reversing aging and age-related diseases. It focuses on achieving rejuvenation across cellular aging hallmarks in human fibroblasts and endothelial cells without the loss cellular identity. The company was founded by Jay Sarkar, Marco Quarta, and Vittorio Sebastiano and is headquartered in Mountain View, CA. | Chairman | 2020-04-30 |
Former positions of David Gobel
| Companies | Position | End |
|---|---|---|
| Volumetric Biotechnologies, Inc. | Director/Board Member | 2019-12-31 |
| Transportation Security Administration | Corporate Officer/Principal | 2013-02-28 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ORGANOVO HOLDINGS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
| Transportation Security Administration | Government |
| Methuselah Foundation | |
Oisin Biotechnologies, Inc.
Oisin Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Oisin Biotechnologies, Inc. operates as a drug development company. It engages in the provision of biological solutions to degenerative aging conditions. The company was founded by Gary Hudson, Kevin Perrott, Matthew Scholz and John Lewis in 2014 and is headquartered in Seattle, WA. | Health Technology |
Methuselah Capital Management LLC
Methuselah Capital Management LLC Investment ManagersFinance Methuselah Capital Management LLC (Methuselah Fund) is a venture capital firm, a subsidiary of Methuselah Foundation founded in 2016 by Sergio Ruiz and David Gobel. The firm is headquartered in Springfield, Virginia. | Finance |
Leucadia Therapeutics, Inc.
Leucadia Therapeutics, Inc. Medical SpecialtiesHealth Technology Leucadia Therapeutics, Inc. develops diagnostic algorithm for Alzheimer disease prevention and treatment. The firm?s therapeutic device is under pre-clinical testing to delay or prevent patients with mild cognitive impairment (MCI) from progressing to Alzheimer's disease. The company was founded by Doug Ethell and is headquartered in Delaware. | Health Technology |
Turn Biotechnologies, Inc.
Turn Biotechnologies, Inc. BiotechnologyHealth Technology Turn Biotechnologies, Inc. engages in the development of solutions for reversing aging and age-related diseases. It focuses on achieving rejuvenation across cellular aging hallmarks in human fibroblasts and endothelial cells without the loss cellular identity. The company was founded by Jay Sarkar, Marco Quarta, and Vittorio Sebastiano and is headquartered in Mountain View, CA. | Health Technology |
| Volumetric Biotechnologies, Inc. |
- Stock Market
- Insiders
- David Gobel
